Sangamo Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.06.17	Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency (PR Newswire)
24.05.17	Gainers & Losers Of May 23: GLYC, PBYI, SGMO, CERS, AGLE... (RTTNews)
16.05.17	Sangamo Gets Fast Track Designation For SB-525 Hemophilia A Gene Therapy (RTTNews)
15.05.17	Sangamo Therapeutics Recognizes International MPS Awareness Day And Celebrates The MPS I And MPS II Communities With Stories Of Hope (PR Newswire)
15.05.17	How These Biotech Stocks are Faring? -- Seattle Genetics, Sangamo Therapeutics, Vertex Pharma, and VIVUS (PR Newswire)
12.05.17	Gainers & Losers Of May 11: SGMO, RNN, XON, MNKD, NVCN... (RTTNews)
11.05.17	FDA Nod For MRK's Keytruda, SGMO Soars On Gene Therapy Deal, OMER Catches Eyes (RTTNews)
10.05.17	Sangamo Therapeutics Reports First Quarter 2017 Financial Results (PR Newswire)
10.05.17	Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy (PR Newswire)
04.05.17	Sangamo Therapeutics Announces Special Regulatory Designations from the FDA for Three Clinical Programs (PR Newswire)
03.05.17	Sangamo Therapeutics Announces First Quarter 2017 Conference Call And Webcast (PR Newswire)
25.04.17	Sangamo Announces The Retirement Of Its Founder And Genome Editing Pioneer Edward Lanphier From The Board Of Directors (PR Newswire)
24.04.17	Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy (PR Newswire)
24.04.17	Sangamo Therapeutics Announces Participation In The ARM 5th Annual Cell & Gene Therapy Investor Day (PR Newswire)
29.03.17	Sangamo Therapeutics Announces Presentation of New Data Demonstrating Significant Reduction of Tau Expression Using Proprietary ZFP Gene Regulation Technology (PR Newswire)
23.03.17	Research Reports Initiation on Biotech Stocks -- Sangamo, Eyegate Pharma, Synthetic Biologics, and Regulus (PR Newswire)
02.03.17	FDA Approves Odactra, JUNO Abandons Rocket, VRML Abuzz, No Tremors For NDRM (RTTNews)
28.02.17	Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results (PR Newswire)
27.02.17	Sangamo Therapeutics Announces Chief Financial Officer Succession (PR Newswire)
27.02.17	Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I (PR Newswire)
21.02.17	Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference Call And Webcast (PR Newswire)
08.02.17	Sangamo Therapeutics Announces Upcoming Presentations At The 13th Annual WORLDSymposium™ Meeting (PR Newswire)
31.01.17	Research Reports Initiation on Biotech Stocks -- Portola Pharma, Tesaro, Sangamo Therapeutics, and Cerus (PR Newswire)
13.01.17	Gainers & Losers Of The Day: TBIO, IMMU, SGMO, BIOC, APRI (RTTNews)
10.01.17	Sangamo Therapeutics Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering (PR Newswire)
06.01.17	Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies (PR Newswire)
06.01.17	Greenbrier Reports First Quarter Results (PR Newswire)
05.01.17	Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A (PR Newswire)
28.12.16	Biotech Stocks on Investors' Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx (PR Newswire)
06.12.16	Sangamo BioSciences Presents Hemophilia A Program Data At The 2016 American Society Of Hematology Meeting (PR Newswire)
01.12.16	Sangamo BioSciences Makes Key Leadership Appointments To Strengthen Clinical And Commercial Capabilities (PR Newswire)
30.11.16	Sangamo's Genome Editing Program for Hemoglobinopathies to Transfer to Biogen's Spin-Off Bioverativ (PR Newswire)
21.09.15	Sangamo Reports Updated Clinical Data From ZFP Therapeutic Program For HIV (RTTNews)
02.09.15	Sangamo And Shire Restructure Collaboration - Quick Facts (RTTNews)
06.12.13	Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Studies (RTTNews)
15.11.13	Sangamo Announces Presentation Of Data From Alzheimer's Disease Program (RTTNews)
29.10.13	INCY's Got More Proof, AKRX Hits New High, ILMN Opens Wallet, RGLS On Watch (RTTNews)
16.10.13	Sangamo BioSciences Announces Third Quarter 2013 Conference Call and Webcast (PR Newswire)
07.10.13	Sangamo BioSciences Announces Presentation At the 2013 Stem Cell Meeting on the Mesa (PR Newswire)
04.10.13	Positive Results, Close of Public Offerings, Grants, Data Presentations and Partnerships - Research Report on Lexicon, Sangamo Biosciences, Immunomedics, NewLink Genetics, and Pacific Biosciences (PR Newswire)
23.09.13	Sangamo Announces Closing Of $74.2 Mln Public Offering Of Common Stock (RTTNews)
23.09.13	Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option (PR Newswire)
18.09.13	Sangamo BioSciences Prices Public Offering Of 6.10 Mln Shares At $10.58/shr (RTTNews)
17.09.13	Sangamo BioSciences Proposes Public Offering Of Common Stock (PR Newswire)
12.09.13	Sangamo BioSciences announces presentation of clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects treated with SB-728-T (PR Newswire)
12.09.13	Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL (PR Newswire)
27.08.13	ACUR Crushed, RGDX Loosens Purse Strings, QRxPharma's Trading Halted (RTTNews)
26.08.13	Sangamo BioSciences To Buy Ceregene (RTTNews)
26.08.13	Sangamo BioSciences to Acquire Ceregene (PR Newswire)
19.08.13	Positive Preliminary Results, R&D Investments, and Financial Results - Research Report on MannKind, Anacor, Sangamo, Stereotaxis, and Columbia Laboratories (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Zuversicht in New York: So bewegt sich der NASDAQ Composite aktuell
19.12.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite zum Start mit Gewinnen
18.12.24		Schwacher Handel in New York: NASDAQ Composite implodiert letztendlich nahezu
18.12.24		Börsianer warten auf Impulse: NASDAQ Composite kaum bewegt
18.12.24		Handel in New York: NASDAQ Composite legt zu
18.12.24		Zuversicht in New York: Anleger lassen NASDAQ Composite zum Handelsstart steigen
17.12.24		Schwacher Handel in New York: NASDAQ Composite legt schlussendlich den Rückwärtsgang ein
16.12.24		Freundlicher Handel in New York: NASDAQ Composite schlussendlich fester

20.12.24

Zuversicht in New York: So bewegt sich der NASDAQ Composite aktuell

19.12.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite zum Start mit Gewinnen

18.12.24

Schwacher Handel in New York: NASDAQ Composite implodiert letztendlich nahezu

18.12.24

Börsianer warten auf Impulse: NASDAQ Composite kaum bewegt

18.12.24

Handel in New York: NASDAQ Composite legt zu

18.12.24

Zuversicht in New York: Anleger lassen NASDAQ Composite zum Handelsstart steigen